Teva Pharmaceutical Industries Limited TEVA
Set alert
42.28 USD +1.58 +3.88%
As of Nov 3, 11:05 AM ET
41.54 Day range 43.34
20.46 52-week range 42.28
- YTD
- +35.47%
- 1 year
- +106.04%
- Open
- 41.91
- Prev close
- 40.70
- Mkt cap
- 49.30B
- Vol
- 4.75M
- Avg vol
- 5.60M
- EPS
- 0.60
- P/E
- 70.45
- Div yield
- 0.00%
More statistics
- Low
- 41.54
- High
- 43.34
- Forward P/E
- 13.18
- Beta
- 0.84
- Short ratio
- 4.40
- Inst. own
- 30.06%
- Dividend
- 0.00
- Ex-div date
- Nov 27, 2017
- Earnings
- Nov 3, 2026
- 50-d avg
- 39.09
- 200-d avg
- 34.58
- 1y target
- 47.58
5Y chart
Events in this range
- Jul 30, 2025Earnings: 0.66; estimate 0.63; surprise 4.76%
- Nov 5, 2025Earnings: 0.78; estimate 0.68; surprise 14.71%
- Jan 28, 2026Earnings: 0.96; estimate 0.65; surprise 47.69%
- Apr 29, 2026Earnings: 0.53; estimate 0.5; surprise 6%
- Jul 29, 2026Earnings: 0.02; estimate 0.08; surprise -75%
- Sep 9, 2026Rating: Leerink Partners · — → Outperform
- Sep 23, 2026Rating: Oppenheimer · — → Outperform
- Oct 1, 2026Rating: TD Cowen · — → Buy
- Oct 12, 2026Rating: JP Morgan · Overweight → Overweight
- Oct 15, 2026Rating: Barclays · Overweight → Overweight
- Nov 2, 2026Rating: HC Wainwright & Co. · — → Buy
- Nov 3, 2026Earnings: —; estimate 0.72; surprise —%
Signals (94)
| Name | Date | Ago |
|---|---|---|
| RSI: Overbought | Oct 12, 2026 | 3 weeks ago |
| MACD: Buy Signal | Aug 17, 2026 | 2 months ago |
| SMA: Bullish | Jul 27, 2026 | 3 months ago |
| SMA: Bullish | Jul 27, 2026 | 3 months ago |
| SMA: Bearish | Jul 13, 2026 | 3 months ago |
| SMA: Bearish | Jul 6, 2026 | 4 months ago |
| SMA: Bullish | Jun 29, 2026 | 4 months ago |
| SMA: Bullish | Jun 22, 2026 | 4 months ago |
| SMA: Bearish | Jun 15, 2026 | 4 months ago |
| SMA: Bearish | Jun 15, 2026 | 4 months ago |
| SMA: Bullish | Apr 27, 2026 | 6 months ago |
| SMA: Bearish | Apr 20, 2026 | 6 months ago |
| SMA: Bullish | Apr 13, 2026 | 6 months ago |
| SMA: Bearish | Mar 2, 2026 | 8 months ago |
| MACD: Sell Signal | Mar 2, 2026 | 8 months ago |
| RSI: Overbought | Nov 24, 2025 | 11 months ago |
| RSI: Overbought | Nov 3, 2025 | 1 year ago |
| SMA: Bullish | Oct 27, 2025 | 1 year ago |
| SMA: Bearish | Oct 20, 2025 | 1 year ago |
| SMA: Bullish | Aug 11, 2025 | 1 year ago |
Newest 20 of 94.
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 47.58 +12.5% upside
Now 42.28
- Target (low)
- 42.00
- Target (mean)
- 47.58
- Target (high)
- 55.00
Ratings (0m) 13 12 buy · 1 hold · 0 sell
- Strong buy4
- Buy8
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 13
- 1 month ago 8
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 0.7302 | 0.60 – 0.89 | 0.00 | 0.0% | 4.24B | -5.3% | 10 |
| Next quarter | 0.75464 | 0.68 – 0.97 | 0.00 | 0.0% | 4.22B | -10.3% | 10 |
| Current year | 2.11 | 1.91 – 2.94 | 0.00 | 0.0% | 16.65B | -3.5% | 13 |
| Next year | 3.09 | 2.86 – 3.35 | 2.11 | +46.6% | 17.23B | +3.5% | 13 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 2, 2026 | HC Wainwright & Co. | Initiated | — | Buy |
| Oct 15, 2026 | Barclays | Maintained | Overweight | Overweight |
| Oct 12, 2026 | JP Morgan | Maintained | Overweight | Overweight |
| Oct 1, 2026 | TD Cowen | Initiated | — | Buy |
| Sep 23, 2026 | Oppenheimer | Initiated | — | Outperform |
| Sep 9, 2026 | Leerink Partners | Initiated | — | Outperform |
| Sep 4, 2026 | UBS | Maintained | Buy | Buy |
| Aug 12, 2026 | Barclays | Maintained | Overweight | Overweight |
| Jul 28, 2026 | Piper Sandler | Maintained | Overweight | Overweight |
| May 6, 2026 | Barclays | Maintained | Overweight | Overweight |
| Apr 30, 2026 | JP Morgan | Maintained | Overweight | Overweight |
| Apr 30, 2026 | UBS | Maintained | Buy | Buy |
| Apr 30, 2026 | Piper Sandler | Reiterated | Overweight | Overweight |
| Apr 30, 2026 | Truist Securities | Maintained | Buy | Buy |
| Apr 9, 2026 | B of A Securities | Maintained | Buy | Buy |
| Mar 4, 2026 | Piper Sandler | Reiterated | Overweight | Overweight |
| Feb 18, 2026 | Truist Securities | Maintained | Buy | Buy |
| Feb 9, 2026 | Goldman Sachs | Maintained | Buy | Buy |
| Jan 30, 2026 | Barclays | Maintained | Overweight | Overweight |
| Jan 29, 2026 | Scotiabank | Maintained | Sector Outperform | Sector Outperform |
| Jan 29, 2026 | Truist Securities | Maintained | Buy | Buy |
| Jan 6, 2026 | Jefferies | Maintained | Buy | Buy |
| Dec 22, 2025 | Piper Sandler | Maintained | Overweight | Overweight |
| Dec 19, 2025 | Goldman Sachs | Maintained | Buy | Buy |
| Dec 16, 2025 | JP Morgan | Maintained | Overweight | Overweight |
| Dec 9, 2025 | B of A Securities | Maintained | Buy | Buy |
| Dec 9, 2025 | Barclays | Initiated | — | Overweight |
| Dec 8, 2025 | Goldman Sachs | Maintained | Buy | Buy |
| Dec 5, 2025 | Scotiabank | Initiated | — | Sector Outperform |
| Nov 6, 2025 | JP Morgan | Maintained | Overweight | Overweight |